Cellular mechanisms of haematopoietic lineage commitment

Lead Research Organisation: University of Oxford
Department Name: UNLISTED

Abstract

This project will analyse individual blood forming cells and the changes they undergo in cancer, during aging and under stress conditions (blood loss, infection) to understand how the body deals with and responds to these challenges.This will be done by using advanced DNA sequencing technology to measure which genes are expressed in each individual cell, and how this pattern changes in the presence of stress hormones, in stem cells that contain mutations that cause leukaemia, and in aged stem cells. The aim is toidentify different types of of blood forming stem cells, andto find outhow these populations change during aging. We will also analyse alsohow stress signals alterthe composition of the hematopoietic stem cell populations and influences their differentiation pattern. This will enable us to design and develop rational therapies to promote or counteract these changes, as required.

Technical Summary

Haematopoiesis has served as a valuable paradigm for how multipotent stem cells are maintained and their differentiation regulated. Thus far elucidation of haematopoietic stem cells and their differentiation, as well as analysis of the alterations they undergo during aging, has generally been hypothesis-driven, enabled by the prospective isolation of discrete cell populations and their functional characterisation. However, recent progress has demonstrated a high degree of complexity of both the haematopoietic stem cell compartment and the pathways by which they form their differentiated progeny, indicating that the current models for how haematopoietic lineage separation are incomplete. With the advent of single cell transcriptome analysis we now have the opportunity to interrogate stem- and progenitor cell populations in a non-biased manner in order to define progenitor populations and their relationships. By combining this technology with novel reporter lines allowing identification of novel stem- and progenitor cell subsets, as well as sensitive readout of erythroid cells and platelets, and the use of lineage tracing, we are now in a position to comprehensively analyse, at the single cell level, the transcriptomes, lineage potentials and cellular relationships within the haematopoietic stem- and progenitor cell compartments. Such studies will allow us to address with a much higher degree of accuracy the impact of aging and oncogenic mutations on the haematopoietic system, and increase our understanding of how immune cell output is modulated by cytokines during microbial insult.

People

ORCID iD

Publications

10 25 50

Related Projects

Project Reference Relationship Related To Start End Award Value
MC_UU_00016/1 01/04/2017 31/03/2022 £3,035,000
MC_UU_00016/2 Transfer MC_UU_00016/1 01/04/2017 31/03/2022 £3,411,000
MC_UU_00016/3 Transfer MC_UU_00016/2 01/04/2017 31/03/2022 £1,366,000
MC_UU_00016/4 Transfer MC_UU_00016/3 01/04/2017 31/03/2020 £3,017,000
MC_UU_00016/5 Transfer MC_UU_00016/4 01/04/2017 31/03/2020 £497,000
MC_UU_00016/6 Transfer MC_UU_00016/5 01/04/2017 31/03/2022 £2,530,000
MC_UU_00016/7 Transfer MC_UU_00016/6 01/04/2017 31/03/2022 £2,018,000
MC_UU_00016/8 Transfer MC_UU_00016/7 01/04/2017 31/03/2018 £1,131,000
MC_UU_00016/9 Transfer MC_UU_00016/8 01/04/2017 31/03/2022 £2,500,000
MC_UU_00016/10 Transfer MC_UU_00016/9 01/04/2017 31/03/2018 £1,171,000
MC_UU_00016/11 Transfer MC_UU_00016/10 01/04/2017 31/03/2022 £1,387,000
MC_UU_00016/12 Transfer MC_UU_00016/11 01/04/2017 31/03/2022 £446,000
 
Description Haematopoiesis - Novel tools for modelling normal and perturbed haematopoiesis
Amount £1,532,023 (GBP)
Funding ID MC_PC_21043 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2022 
End 03/2027
 
Description Hierarchical organization of haematopoietic stem- and progenitor cell populations during steady state and stress haematopoiesis
Amount £3,329,263 (GBP)
Funding ID MC_UU_00029/9 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2022 
End 03/2027
 
Description Transcriptional and epigenetic mechanisms of HSC subtype diversification
Amount £462,191 (GBP)
Funding ID BB/V002198/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2020 
End 11/2023
 
Description Hematopoiesis and leukemogenesis 
Organisation CeMM Research Center for Molecular Medicine
Country Austria 
Sector Academic/University 
PI Contribution Genetic modelling of hematopoiesis
Collaborator Contribution Scientific discussion, methodology
Impact Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, Rasmussen KD, Luc S, Bilbao D, O'Carroll D, Jacobsen SE, Nerlov C. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 2011 Nov 8. doi: 10.1038/emboj.2011.390 Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood. 2011 Sep 29;118(13):3613-21. Kaveri D., P. Kastner, D. Dembélé, C. Nerlov, S. Chan and P. Kirstetter. 2013. ß-catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood 122: 694-704. Zhang,H., M. Alberich-Jordà, G. Amabile, H. Yang, P.B. Staber, A. DiRuscio, R.S. Welner, A. Ebralidze, J. Zhang, E. Levantini, V. Lefebvre, P.J.M. Valk, R. Delwel, M. Hoogenkamp, C. Nerlov, J. Cammenga, B. Saez, D.T. Scadden, C. Bonifer, M. Ye and D.G. Tenen. 2013. Sox4 is a key oncogenic target in C/EBPa mutant Acute Myeloid Leukemia. Cancer Cell 24: 575-88. Grebien, F., M. Vedadi, M. Getlik, R. Giambruno, A. Grover, R. Avellino, A. Skucha, S. Vittori, E. Kuznetsova, D. Smil, D. Barsyte-Lovejoy, F. Li, G. Poda, M. Schapira, H. Wu, A. Dong, G. Senisterra, A. Stukalov, K.V.M. Huber, A. Schönegger, M. Bilban, C. Bock, P.J. Brown, J. Zuber, K.L. Bennett, R. Al-awar, R. Delwel, C. Nerlov, C.H. Arrowsmith and G. Superti-Furga. 2015. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia. Nat. Chem. Biol. 11: 571-8.
Start Year 2018
 
Description Hematopoiesis and leukemogenesis 
Organisation Harvard University
Department Harvard Stem Cell Institute
Country United States 
Sector Academic/University 
PI Contribution Genetic modelling of hematopoiesis
Collaborator Contribution Scientific discussion, methodology
Impact Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, Rasmussen KD, Luc S, Bilbao D, O'Carroll D, Jacobsen SE, Nerlov C. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 2011 Nov 8. doi: 10.1038/emboj.2011.390 Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood. 2011 Sep 29;118(13):3613-21. Kaveri D., P. Kastner, D. Dembélé, C. Nerlov, S. Chan and P. Kirstetter. 2013. ß-catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood 122: 694-704. Zhang,H., M. Alberich-Jordà, G. Amabile, H. Yang, P.B. Staber, A. DiRuscio, R.S. Welner, A. Ebralidze, J. Zhang, E. Levantini, V. Lefebvre, P.J.M. Valk, R. Delwel, M. Hoogenkamp, C. Nerlov, J. Cammenga, B. Saez, D.T. Scadden, C. Bonifer, M. Ye and D.G. Tenen. 2013. Sox4 is a key oncogenic target in C/EBPa mutant Acute Myeloid Leukemia. Cancer Cell 24: 575-88. Grebien, F., M. Vedadi, M. Getlik, R. Giambruno, A. Grover, R. Avellino, A. Skucha, S. Vittori, E. Kuznetsova, D. Smil, D. Barsyte-Lovejoy, F. Li, G. Poda, M. Schapira, H. Wu, A. Dong, G. Senisterra, A. Stukalov, K.V.M. Huber, A. Schönegger, M. Bilban, C. Bock, P.J. Brown, J. Zuber, K.L. Bennett, R. Al-awar, R. Delwel, C. Nerlov, C.H. Arrowsmith and G. Superti-Furga. 2015. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia. Nat. Chem. Biol. 11: 571-8.
Start Year 2018
 
Description Hematopoiesis and leukemogenesis 
Organisation Medical Research Council (MRC)
Department MRC Molecular Haematology Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Genetic modelling of hematopoiesis
Collaborator Contribution Scientific discussion, methodology
Impact Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, Rasmussen KD, Luc S, Bilbao D, O'Carroll D, Jacobsen SE, Nerlov C. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 2011 Nov 8. doi: 10.1038/emboj.2011.390 Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood. 2011 Sep 29;118(13):3613-21. Kaveri D., P. Kastner, D. Dembélé, C. Nerlov, S. Chan and P. Kirstetter. 2013. ß-catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood 122: 694-704. Zhang,H., M. Alberich-Jordà, G. Amabile, H. Yang, P.B. Staber, A. DiRuscio, R.S. Welner, A. Ebralidze, J. Zhang, E. Levantini, V. Lefebvre, P.J.M. Valk, R. Delwel, M. Hoogenkamp, C. Nerlov, J. Cammenga, B. Saez, D.T. Scadden, C. Bonifer, M. Ye and D.G. Tenen. 2013. Sox4 is a key oncogenic target in C/EBPa mutant Acute Myeloid Leukemia. Cancer Cell 24: 575-88. Grebien, F., M. Vedadi, M. Getlik, R. Giambruno, A. Grover, R. Avellino, A. Skucha, S. Vittori, E. Kuznetsova, D. Smil, D. Barsyte-Lovejoy, F. Li, G. Poda, M. Schapira, H. Wu, A. Dong, G. Senisterra, A. Stukalov, K.V.M. Huber, A. Schönegger, M. Bilban, C. Bock, P.J. Brown, J. Zuber, K.L. Bennett, R. Al-awar, R. Delwel, C. Nerlov, C.H. Arrowsmith and G. Superti-Furga. 2015. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia. Nat. Chem. Biol. 11: 571-8.
Start Year 2018
 
Description Hematopoiesis and leukemogenesis 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Genetic modelling of hematopoiesis
Collaborator Contribution Scientific discussion, methodology
Impact Mancini E, Sanjuan-Pla A, Luciani L, Moore S, Grover A, Zay A, Rasmussen KD, Luc S, Bilbao D, O'Carroll D, Jacobsen SE, Nerlov C. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J. 2011 Nov 8. doi: 10.1038/emboj.2011.390 Kharazi S, Mead AJ, Mansour A, Hultquist A, Böiers C, Luc S, Buza-Vidas N, Ma Z, Ferry H, Atkinson D, Reckzeh K, Masson K, Cammenga J, Rönnstrand L, Arai F, Suda T, Nerlov C, Sitnicka E, Jacobsen SE. Impact of gene dosage, loss of wild-type allele, and FLT3 ligand on Flt3-ITD-induced myeloproliferation. Blood. 2011 Sep 29;118(13):3613-21. Kaveri D., P. Kastner, D. Dembélé, C. Nerlov, S. Chan and P. Kirstetter. 2013. ß-catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL. Blood 122: 694-704. Zhang,H., M. Alberich-Jordà, G. Amabile, H. Yang, P.B. Staber, A. DiRuscio, R.S. Welner, A. Ebralidze, J. Zhang, E. Levantini, V. Lefebvre, P.J.M. Valk, R. Delwel, M. Hoogenkamp, C. Nerlov, J. Cammenga, B. Saez, D.T. Scadden, C. Bonifer, M. Ye and D.G. Tenen. 2013. Sox4 is a key oncogenic target in C/EBPa mutant Acute Myeloid Leukemia. Cancer Cell 24: 575-88. Grebien, F., M. Vedadi, M. Getlik, R. Giambruno, A. Grover, R. Avellino, A. Skucha, S. Vittori, E. Kuznetsova, D. Smil, D. Barsyte-Lovejoy, F. Li, G. Poda, M. Schapira, H. Wu, A. Dong, G. Senisterra, A. Stukalov, K.V.M. Huber, A. Schönegger, M. Bilban, C. Bock, P.J. Brown, J. Zuber, K.L. Bennett, R. Al-awar, R. Delwel, C. Nerlov, C.H. Arrowsmith and G. Superti-Furga. 2015. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPa N-terminal leukemia. Nat. Chem. Biol. 11: 571-8.
Start Year 2018